<br /><br />E1308:<br />A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Disclosures

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Slide 3

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Background: HPV+ OP SCCa

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Rationale: Cetuximab based Induction CT

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Slide 6

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Endpoints

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Statistics

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Results

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Slide 10

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Results: Acute Toxicity

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Late Toxicity

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Response: Induction

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Response: Following Cetux/IMRT

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Endpoint: 2yr PFS and OS

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

PFS and Survival: Dose

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Low Dose: T stage and N stage

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Smoking: PFS and Survival

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Best Outcome: <T4, T1-N2b, <10 pk-yr

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

First Failure Patterns: Low-dose pts

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Summary

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Conclusions

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Designed and conducted by:

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting